20VC: 23andMe's Anne Wojcicki on How To Appro...

Up next

20VC: Why "Pacing the Frontier" is BS | Instinct Raising $1BN at $10BN & Meta Launches Muse | Miro Sells for $1.35BN After a $17.5BN Valuation | Mistral Raises €3BN & Could Sam Bankman-Fried Win His Freedom?

AGENDA: 03:40 Dario Calls to "Pace the Frontier" 11:30 Why the Fed Will Raid Anthropic if Needed 21:50 Meta Launches Muse to Take On Instinct 28:30 Instinct Raising $1BN at $10BN—Would You Invest? 39:55 Miro Sells for $1.35BN After a $17.5BN Valuation 47:45 Could Sam Bankman-Frie ... Show more

. 1h 15min

20VC: How LPs Allocate to Venture in 2026: What They Want, What They Do Not Want | Why Fund Multiple Does Not Matter Without a Timeline | Why Velocity of Cashback is the Most Important Thing with David Morehead, CIO @ Baylor

David Morehead is one of the most respected CIOs in the endowment fund world as Chief Investment Officer at Baylor University, overseeing its $2.6BN endowment. Before joining Baylor in 2011, he was a senior portfolio manager at several Chicago hedge funds, investing across corpor ... Show more

. 1h 8min

Recommended Episodes

372: Biotech Billionaire Anne Wojcicki, Cofounder and CEO of 23andMe

The Foundr Podcast with Nathan Chan

You’ve heard data has the power to make or break a business. Nobody knows this more than Anne Wojcicki, co-founder of biotech giant 23andMe. After 15 years of leveraging data to build a game-changing company, Wojcicki made headlines this summer when she became the latest self-mad ... Show more

. 53min 20sec

23andMe's Fatal Flaw | Great Expectorations | 1

Business Wars

When Silicon Valley power-player Anne Wojcicki sees gold in genetics, she forms 23andMe. She wants to bring genetic testing to the masses. But behind the hype and celebrity endorsements, can she build a company that’s selling more than just an expensive novelty product? Be the fi ... Show more

. 36min 42sec

How 23andMe went from a $6 billion valuation to trading for pennies

World Changing Ideas

Cofounder and CEO of 23andMe, Anne Wojcicki, wants to take the public company private. Founded in 2006, the DNA-testing startup was valued at $6 billion in 2021. Now, it’s trading for less than a dollar. So what happened? ‘Fast Company’ senior writer Ainsley Harris breaks down 23 ... Show more

. 54min 45sec

23andMe's Fatal Flaw | Guess Who’s Back | 3

Business Wars

Just when it looked like 23andMe was selling to Regeneron Pharmaceuticals, founder Anne Wojcicki placed a bid through her new nonprofit in an attempt to win it back at the eleventh hour. Lila MacLellan, Senior Writer at Fortune, joins David to discuss Wojcicki’s leadership style, ... Show more

. 37min 55sec